L’utilisation des insulines biosimilaires en 2023
Résumé
Un biosimilaire est un médicament qui est très
semblable à un médicament biologique. Il a été démontré qu’il ne présente aucune différence cliniquement significative avec le médicament de référence, malgré des différences mineures dans les composants cliniquement inactifs. Étant donné l’augmentation des taux de diabète et des coûts pour le système de santé canadien, l’utilisation d’insulines biosimilaires vise à diminuer le coût des produits biologiques. Le présent article passe en revue les produits biosimilaires disponibles approuvés au Canada, les études évaluant l’innocuité et l’efficacité, ainsi que les avantages et les préoccupations possibles concernant le passage aux insulines biosimilaires.
Références
Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014 Oct;127(10 Suppl):S25-38.
Fact Sheet: Biosimilar Biologic Drugs. Health Canada. http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/fs-fi/fs-fi_seb-pbu_07-2006-eng.php.
Diabetes, Biologic Drugs, and Biosimilar Insulins: A Position Statement. Diabetes Canada, 2020.
Keon, J. “Op-ed: The case for an Ontario biosimilar switching policy.” Biosimilars Canada, November 2021. https://biosimilarscanada.ca/news/news-releases.
Joshi SR, et al. Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective. Expert Opin Biol Th. 2022:1-12.
Blevins, TC, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17(8):726-733.
Rosenstock J, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015;17(8):734-741.
Garg SK, et al. Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 1 diabetes also using insulin glargine—SORELLA 1 study. Diabetes Technol Ther. 2017;19(9):516-526.
Derwahl, K-M, et al. Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 2 diabetes, also using insulin glargine: SORELLA 2 study. Diabetes Technol Ther. 2018;20(1): 49-58.
Garg, S K, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: a randomized open-label trial (GEMELLI 1). Diabetes Technol Ther. 2020;222):85-95.
Blevins, TC, et al. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: results of the INSTRIDE 1 phase III study. Diabetes Obes Metab. 2018;20(8): 1944-1950.
Blevins, TC, et al. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: results of the phase III INSTRIDE 2 study. Diabetes Obes Metab. 2019;21(1): 129-135.
Shah, V N, et al. Efficacy, safety, and immunogenicity of insulin aspart biosimilar SAR341402 compared with originator insulin aspart in adults with diabetes (GEMELLI 1): a subgroup analysis by prior type of mealtime insulin. Diabetes Ther. 2021;12.2:557-568.
Blevins TC, Barve A, Raiter Y, Aubonnet P, Athalye S, Sun B, et al. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. Diabetes Obes Metab. 2020 Mar;22(3):365-372.
Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. 2018. PLoS ONE 13(4):e0195012
Yang, L-J, et al. Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis. BMC Endocr Disord. 2022;22(1):1-11.
Thrasher J, et al. Diabetes technol Ther. 2020;22(9): 666-673.
Wilsdon T, et al. Biosimilars: a global roadmap for policy sustainability. Charles River Associates. 2022.
Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017 Oct 14;4(2):209-18.
Morris Dd. Biosimilar insulins: an in-depth guide. J Diabetes Nurse. 2022;26(1):1-9.
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Diabetes & Endocrinology Today 2023
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
